4.7 Editorial Material

Does Insulin Therapy Promote, Reduce, or Have a Neutral Effect on Cancers?

期刊

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jama.2010.60

关键词

-

向作者/读者索取更多资源

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Endocrinology & Metabolism

Thyroid Dysfunction and Cardiovascular Events in Patients With Dysglycemia

Reema Shah, Steven Orlov, Guillaume Pare, Hertzel C. Gerstein

Summary: The objective of this study was to assess the association of thyroid function and thyroid hormone replacement with cardiovascular outcomes in high-risk individuals. The study found that subclinical hypothyroidism predicts future cardiovascular events and mortality in high-risk individuals.

CANADIAN JOURNAL OF DIABETES (2023)

Letter Endocrinology & Metabolism

Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial

Hertzel C. Gerstein, Emil Wolsk, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Sibylle Hess, Lars Kober, Aldo P. Maggioni, John J. V. McMurray, Jeffrey L. Probstfield, Matthew C. Riddle, Jean-Claude Tardif, Marc A. Pfeffer

DIABETES OBESITY & METABOLISM (2023)

Article Endocrinology & Metabolism

Nailfold capillaroscopy and deep learning in diabetes

Reema Shah, Jeremy Petch, Walter Nelson, Karsten Roth, Michael D. D. Noseworthy, Marzyeh Ghassemi, Hertzel C. C. Gerstein

Summary: This study demonstrates the potential of using video capillaroscopy images and machine learning techniques to diagnose diabetes and its complications.

JOURNAL OF DIABETES (2023)

Article Endocrinology & Metabolism

Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers

Jean-Francois Yale, Aude Roborel de Climens, Naresh Aggarwal, Terry Dex, Hertzel C. C. Gerstein, Stewart Harris, Irene Hramiak, John Stewart, Lawrence A. A. Leiter

Summary: For individuals with type 2 diabetes mellitus who do not reach their target glycated hemoglobin A1C levels with basal insulin therapy, additional treatment with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) may be necessary. This study examined the ease of transitioning from insulin glargine 100 U/ml to the fixed-ratio combination (FRC) therapy iGlarLixi. The results showed that both patients and healthcare professionals found the iGlarLixi SoloStar pen easy to use and would recommend it to others, indicating a consensus on the simplicity of transitioning to iGlarLixi.

DIABETES THERAPY (2023)

Article Cardiac & Cardiovascular Systems

Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial

Hertzel C. Gerstein, Zhuoru Li, Chinthanie Ramasundarahettige, Seungjae Baek, Kelley R. H. Branch, Stefano Del Prato, Carolyn S. P. Lam, Renato D. Lopes, Richard Pratley, Julio Rosenstock, Naveed Sattar

Summary: In the AMPLITUDE-O trial, adding either 4 mg or 6 mg weekly of efpeglenatide reduced major adverse cardiovascular events in people with type 2 diabetes. The benefits of efpeglenatide appear to be dose-related.

CIRCULATION (2023)

Article Cardiac & Cardiovascular Systems

Twenty Years of Cardiovascular Complications and Risk Factors in Patients With Type 2 Diabetes: A Nationwide Swedish Cohort Study

Naveed Sattar, John McMurray, Jan Boren, Araz Rawshani, Elmir Omerovic, Niklas Berg, Janita Halminen, Kristoffer Skoglund, Bjorn Eliasson, Hertzel C. Gerstein, Darren K. McGuire, Deepak Bhatt, Aidin Rawshani

Summary: The goal of this study was to analyze the trends in cardiovascular events and cardiometabolic risk factor levels in individuals with type 2 diabetes (T2D) and matched control subjects. The results showed a decreasing trend in the risk and rates of atherosclerotic complications and heart failure in individuals with T2D, although the incidence of heart failure has plateaued in recent years. Modifiable risk factors within target levels were associated with lower risks for outcomes.

CIRCULATION (2023)

Article Endocrinology & Metabolism

Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis

Hertzel C. Gerstein, Shun-Fu Lee, Guillaume Pare, M. Angelyn Bethel, Helen M. Colhoun, Anastasia Hoover, Mark Lakshmanan, Yanzhu Lin, Valentino Pirro, Hui-Rong Qian, Giacomo Ruotolo, Lars Ryden, Jonathan M. Wilson, Kevin L. Duffin

Summary: The glucagon-like peptide-1 receptor agonist dulaglutide reduces the risk of major adverse cardiovascular events (MACE) and is associated with changes in certain protein biomarkers such as N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and growth differentiation factor 15 (GDF-15) that are also associated with MACE.

DIABETES CARE (2023)

Article Endocrinology & Metabolism

Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis

Fady T. Botros, Hertzel C. Gerstein, Raleigh Malik, Claudia Nicolay, Anastasia Hoover, Ibrahim Turfanda, Helen M. Colhoun, Jonathan E. Shaw

Summary: Dulaglutide (DU) 1.5 mg was found to improve kidney function and reduce the risk of negative kidney-related outcomes in patients with type 2 diabetes. It was observed that DU reduced the occurrence of sustained eGFR decline and slowed the decline in eGFR slope. These effects were consistent among different subgroups.

DIABETES CARE (2023)

Article Medicine, General & Internal

A culturally tailored personaliseD nutrition intErvention in South ASIan women at risk of Gestational Diabetes Mellitus ( DESI-GDM): a randomised controlled trial protocol

Rosain N. Stennett, Kristi B. Adamo, Sonia S. Anand, Harpreet S. Bajaj, Shrikant Bangdiwala, Dipika Desai, Hertzel C. Gerstein, Sujane Kandasamy, Farah Khan, Scott A. Lear, Sarah D. McDonald, Tayler Pocsai, Paul Ritvo, Andrea Rogge, Karleen M. Schulze, Diana Sherifali, Jennifer C. Stearns, Gita Wahi, Natalie C. Williams, Michael A. Zulyniak, Russell J. de Souza

Summary: This study aims to evaluate the effectiveness and participant acceptability of a culturally tailored, personalised nutrition intervention on the glucose area under the curve in pregnant women of South Asian ancestry with gestational diabetes risk factors. A total of 190 South Asian pregnant women will be enrolled and randomly assigned to two groups to observe the changes in their glucose levels. Findings will be disseminated through scientific publications and community-orientated strategies.

BMJ OPEN (2023)

Article Cardiac & Cardiovascular Systems

Relationship between remnant cholesterol and risk of heart failure in participants with diabetes mellitus

Ruoting Wang, Hertzel C. Gerstein, Harriette G. C. Van Spall, Gregory Y. H. Lip, Ivan Olier, Sandra Ortega-Martorell, Lehana Thabane, Zebing Ye, Guowei Li

Summary: This study found a significant association between calculated remnant cholesterol (RC) and risk of heart failure (HF) in patients with diabetes mellitus (DM). Elevated RC levels were associated with an increased risk of HF, highlighting the importance of RC management in patients with DM for HF risk management.

EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES (2023)

Article Cardiac & Cardiovascular Systems

Diet, cardiovascular disease, and mortality in 80 countries

Andrew Mente, Mahshid Dehghan, Sumathy Rangarajan, Martin O'Donnell, Weihong Hu, Gilles Dagenais, Andreas Wielgosz, Scott A. Lear, Li Wei, Rafael Diaz, Alvaro Avezum, Patricio Lopez-Jaramillo, Fernando Lanas, Sumathi Swaminathan, Manmeet Kaur, K. Vijayakumar, Viswanathan Mohan, Rajeev Gupta, Andrzej Szuba, Romaina Iqbal, Rita Yusuf, Noushin Mohammadifard, Rasha Khatib, Nafiza Mat Nasir, Kubilay Karsidag, Annika Rosengren, Afzalhussein Yusufali, Edelweiss Wentzel-Viljoen, Jephat Chifamba, Antonio Dans, Khalid F. Alhabib, Karen Yeates, Koon Teo, Hertzel C. Gerstein, Salim Yusuf

Summary: A healthy diet score based on fruits, vegetables, nuts, legumes, fish, and whole-fat dairy is associated with lower risk of all-cause mortality, cardiovascular disease, myocardial infarction, and stroke in a global population. This score exhibits stronger associations with death or CVD compared to other common diet scores.

EUROPEAN HEART JOURNAL (2023)

Article Multidisciplinary Sciences

Determinants of sustained stabilization of beta-cell function following short-term insulin therapy in type 2 diabetes

Ravi Retnakaran, Jiajie Pu, Alexandra Emery, Stewart B. Harris, Sonja M. Reichert, Hertzel C. Gerstein, Natalia McInnes, Caroline K. Kramer, Bernard Zinman

Summary: Induction with short-term insulin therapy followed by maintenance with metformin can stabilize beta-cell function in early type 2 diabetes. The study found that initial reversibility of beta-cell dysfunction and preserved hepatic insulin sensitivity are associated with sustained stabilization of beta-cell function.

NATURE COMMUNICATIONS (2023)

Article Endocrinology & Metabolism

Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial

Liam Mc Morrow, Frauke Becker, Ruth L. Coleman, Hertzel C. Gerstein, Lars Ryden, Stefan Schoeder, Alastair M. Gray, Jose Leal, Rury R. Holman, ACE Study Grp

Summary: This study analyzed the use of acarbose in Chinese coronary heart disease patients with impaired glucose tolerance. The results showed that patients using acarbose had higher costs compared to placebo, but there was no significant difference in QALYs.

JOURNAL OF DIABETES (2023)

Letter Cardiac & Cardiovascular Systems

Relationship between remnant cholesterol and risk of heart failure in participants with diabetes mellitus: Reply

Ruoting Wang, Hertzel C. Gerstein, Harriette G. C. Van Spall, Gregory Y. H. Lip, Ivan Olier, Sandra Ortega-Martorell, Lehana Thabane, Zebing Ye, Guowei Li

EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES (2023)

Article Endocrinology & Metabolism

Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial

Hertzel C. Gerstein, Rajibul Mian, Chinthanie Ramasundarahettige, Kelley R. H. Branch, Stefano Del Prato, Carolyn S. P. Lam, Renato D. Lopes, Richard Pratley, Julio Rosenstock, Naveed Sattar

Summary: This study aimed to estimate the incidence of MACE and composite kidney outcome across eGFR and UACR levels, and to determine whether efpeglenatide's effect varies with these indices. The results showed that eGFR, UACR, and KDIGO category have different relationships to incident cardiovascular and kidney outcomes, and the beneficial effect of efpeglenatide on these outcomes is independent of kidney-related risk category.

DIABETES OBESITY & METABOLISM (2023)

暂无数据